These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33615106)

  • 1. Renal Phosphate Handling: Independent Effects of Circulating FGF23, PTH, and Calcium.
    McKenna MJ; Crowley RK; Twomey PJ; Kilbane MT
    JBMR Plus; 2021 Feb; 5(2):e10437. PubMed ID: 33615106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Unexplained Mild Hypophosphatemia and Very High Serum FGF23 Concentrations.
    Bosman A; Ratsma DM; van der Eerden BC; Zillikens MC
    JBMR Plus; 2023 Oct; 7(10):e10790. PubMed ID: 37808399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congenital hypophosphataemia in adults: determinants of bone turnover markers and amelioration of renal phosphate wasting following total parathyroidectomy.
    McKenna MJ; Martin-Grace J; Crowley R; Twomey PJ; Kilbane MT
    J Bone Miner Metab; 2019 Jul; 37(4):685-693. PubMed ID: 30238432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
    Takashi Y; Toyokawa K; Oda N; Muta Y; Yokomizo H; Fukumoto S; Kawanami D
    Front Endocrinol (Lausanne); 2022; 13():1004624. PubMed ID: 36531500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation.
    Tomida K; Hamano T; Ichimaru N; Fujii N; Matsui I; Nonomura N; Tsubakihara Y; Rakugi H; Takahara S; Isaka Y
    Bone; 2012 Oct; 51(4):729-36. PubMed ID: 22796419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parathyroid Hormone, Fibroblast Growth Factor 23, and Parameters of Phosphate Reabsorption.
    Phelps KR; Mason DL
    Am J Nephrol; 2018; 47(5):343-351. PubMed ID: 29779023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia.
    Hartley IR; Gafni RI; Roszko KL; Brown SM; de Castro LF; Saikali A; Ferreira CR; Gahl WA; Pacak K; Blau JE; Boyce AM; Salusky IB; Collins MT; Florenzano P
    J Bone Miner Res; 2022 Nov; 37(11):2174-2185. PubMed ID: 36093861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia.
    Giralt M; Chocron S; Ferrer R; Ariceta G
    Pediatr Nephrol; 2021 Apr; 36(4):1025-1028. PubMed ID: 33492457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormalities in renal tubular phosphate handling in children with sickle cell disease.
    Raj VM; Freundlich M; Hamideh D; Alvarez O; Seeherunvong W; Abitbol C; Katsoufis C; Chandar J; Ruiz P; Zilleruelo G
    Pediatr Blood Cancer; 2014 Dec; 61(12):2267-70. PubMed ID: 25132581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M; Koch TA; Bregman DB
    J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative changes of FGF23 in patients undergoing surgery for primary hyperparathyroidism.
    Fořtová M; Hanousková L; Valkus M; Čepová J; Průša R; Kotaška K
    Endocr Connect; 2022 Jan; 11(1):. PubMed ID: 34860179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets.
    Alon US; Levy-Olomucki R; Moore WV; Stubbs J; Liu S; Quarles LD
    Clin J Am Soc Nephrol; 2008 May; 3(3):658-64. PubMed ID: 18256372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The concurrence of hypoparathyroidism provides new insights to the pathophysiology of X-linked hypophosphatemic rickets.
    Lyles KW; Burkes EJ; McNamara CR; Harrelson JM; Pickett JP; Drezner MK
    J Clin Endocrinol Metab; 1985 Apr; 60(4):711-7. PubMed ID: 4038714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency.
    Frazier R; Hodakowski A; Cai X; Lee J; Zakarija A; Stein B; David V; Wolf M; Isakova T; Mehta R
    Bone; 2020 Dec; 141():115559. PubMed ID: 32730929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced phosphate reabsorption unrelated to parathyroid hormone after renal transplantation: implications for the pathogenesis of hyperparathyroidism in chronic renal failure.
    Parfitt AM; Kleerekoper M; Cruz C
    Miner Electrolyte Metab; 1986; 12(5-6):356-62. PubMed ID: 3543637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct phenotype of kidney stone formers with renal phosphate leak.
    Dhayat NA; Lüthi D; Schneider L; Mattmann C; Vogt B; Fuster DG
    Nephrol Dial Transplant; 2019 Jan; 34(1):129-137. PubMed ID: 29939320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Clearance of Fibroblast Growth Factor-23 (FGF23) and its Fragments in Humans.
    Sharma S; Katz R; Ginsberg C; Bullen A; Vallon V; Thomson S; Moe OW; Hoofnagle AN; de Leeuw PW; Kroon AA; Houben AJHM; Ix JH
    J Bone Miner Res; 2022 Jun; 37(6):1170-1178. PubMed ID: 35373859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tubular phosphate transport: a comparison between different methods of urine sample collection in FGF23-dependent hypophosphatemic syndromes.
    Arcidiacono GP; Camozzi V; Zaninotto M; Tripepi G; Fusaro M; Torres MO; Zanchetta F; Cannito M; Cecchinato A; Diogo M; Peleg Falb M; Plebani M; Simioni P; Sella S; Giannini S
    Clin Chem Lab Med; 2024 May; 62(6):1126-1132. PubMed ID: 38295343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTH and FGF23 Exert Interdependent Effects on Renal Phosphate Handling: Evidence From Patients With Hypoparathyroidism and Hyperphosphatemic Familial Tumoral Calcinosis Treated With Synthetic Human PTH 1-34.
    Ovejero D; Hartley IR; de Castro Diaz LF; Theng E; Li X; Gafni RI; Collins MT
    J Bone Miner Res; 2022 Feb; 37(2):179-184. PubMed ID: 34464000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone involvement and mineral metabolism in Williams' syndrome.
    Palmieri S; Bedeschi MF; Cairoli E; Morelli V; Lunati ME; Scillitani A; Carnevale V; Lalatta F; Barbieri AM; Orsi E; Spada A; Chiodini I; Eller-Vainicher C
    J Endocrinol Invest; 2019 Mar; 42(3):337-344. PubMed ID: 30030744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.